

January 23, 2026

**BSE Limited**

**Code: 532321**

1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**National Stock Exchange of India Limited**

**Code: Zyduslife**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Re.: Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated January 23, 2026, titled “**Closure of USFDA inspection at Zydus’ Unit-2 manufacturing plant at Ankleshwar**”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**

**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Encl.: As above**



## **Closure of USFDA inspection at Zydus' Unit – 2 manufacturing plant at Ankleshwar**

*Ahmedabad, India, 23 January, 2026*

We wish to inform that the USFDA conducted an inspection at the group's Unit – 2 manufacturing plant at Ankleshwar, Gujarat. The inspection was conducted from 19<sup>th</sup> to 23<sup>rd</sup> January, 2026 and concluded with 3 observations. There were no data integrity related observations. The Company will closely work with the USFDA to address the observations expeditiously.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878